Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
AIDS and Behavior|April 17, 2026
Written on the Skin: Participants' Perspectives on Scarring, Discolouration and Implant Site Reactions Experienced During a Phase I Clinical Trial for a Subdermal HIV Prevention Implant in KwaZulu-Natal, South AfricaEmma Durden, Eliza Govender, Aphiwe Dlokweni, et al.AIDS Care|March 6, 2026
"There is nobody who wouldn't like to": understanding the motivations behind women's participation in a Phase I clinical trial for a subdermal HIV prevention implant in KwaZulu-Natal, South AfricaEmma Durden, Eliza Govender, Aphiwe Dlokweni, et al.Journal of the International AIDS Society|September 12, 2019
Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trialLeila E Mansoor, Nonhlanhla Yende-Zuma, Cheryl Baxter, et al.Journal of the International AIDS Society|July 5, 2022
Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South AfricaLeila E Mansoor, Lara Lewis, Cherise L Naicker, et al.The New England Journal of Medicine|August 6, 2015
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 InfectionSalim S Abdool Karim, Quarraisha Abdool Karim, Ayesha B M Kharsany, et al.Journal of the International AIDS Society|February 21, 2025
Acceptability of an annual tenofovir alafenamide implant for HIV prevention in South African women: findings from the CAPRISA 018 Phase I clinical trialTanuja N Gengiah, Craig J Heck, Lara Lewis, et al.Trials|December 21, 2014
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trialLeila E Mansoor, Quarraisha Abdool Karim, Kathryn T Mngadi, et al.The Lancet. HIV|June 30, 2025
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-human, phase 1 trialTanuja N Gengiah, Lara Lewis, Ishana Harkoo, et al.Trials|March 10, 2011
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trialQuarraisha Abdool Karim, Ayesha Bm Kharsany, Janet A Frohlich, et al.Science (New York, N.Y.)|July 21, 2010
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenQuarraisha Abdool Karim, Salim S Abdool Karim, Janet A Frohlich, et al.Pageof 4